EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma.
EVI1
clear cell renal cell carcinoma
everolimus
genetic association
mTOR
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
20
11
2019
revised:
10
01
2020
accepted:
25
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
The transcription factor EVI1 plays an oncogenic role in several types of neoplasms by promoting aggressive cancer features. EVI1 contributes to epigenetic regulation and transcriptional control, and its overexpression has been associated with enhanced PI3K-AKT-mTOR signaling in some settings. These observations raise the possibility that EVI1 influences the prognosis and everolimus-based therapy outcome of clear cell renal cell carcinoma (ccRCC). Here, gene expression and protein immunohistochemical studies of ccRCC show that EVI1 overexpression is associated with advanced disease features and with poorer outcome-particularly in the CC-e.3 subtype defined by The Cancer Genome Atlas. Overexpression of an oncogenic EVI1 isoform in RCC cell lines confers substantial resistance to everolimus. The
Identifiants
pubmed: 32012804
pii: cancers12020300
doi: 10.3390/cancers12020300
pmc: PMC7072453
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : SGR-2017-449
Organisme : Instituto de Salud Carlos III
ID : PI15/00854
Organisme : Instituto de Salud Carlos III
ID : PI18/01029
Organisme : Telemartón "Todos Somos Raros, Todos Somos Unicos"
ID : P35
Organisme : Generalitat de Catalunya
ID : CERCA program
Organisme : European Regional Development Fund
ID : IDIBELL program
Déclaration de conflit d'intérêts
O.C. and M.A.P. are recipients of an unrestricted grant from Roche Pharma to finance the ProCURE research program, which was paid to the Catalan Institute of Oncology (2017).
Références
Cancer Res. 2017 Apr 15;77(8):2148-2160
pubmed: 28209621
Blood. 2011 Jan 6;117(1):234-41
pubmed: 20855866
FEBS Lett. 2008 Aug 6;582(18):2761-7
pubmed: 18619962
Oncotarget. 2015 Aug 14;6(23):19500-13
pubmed: 25944619
Cancer Res. 2016 Sep 1;76(17):5103-14
pubmed: 27197191
Hypertension. 2017 Jul 24;:
pubmed: 28739976
Blood. 2003 Feb 1;101(3):837-45
pubmed: 12393383
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Nat Commun. 2018 Feb 21;9(1):741
pubmed: 29467463
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):E2885-94
pubmed: 23858473
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Leukemia. 2010 May;24(5):942-9
pubmed: 20357826
Oncotarget. 2011 Jul;2(7):575-86
pubmed: 21795762
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343622
Mol Oncol. 2013 Jun;7(3):647-68
pubmed: 23517670
Eur Urol. 2009 Feb;55(2):452-9
pubmed: 18692951
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Lung Cancer. 2007 Jan;55(1):43-51
pubmed: 17109992
Oncol Lett. 2019 Aug;18(2):1847-1855
pubmed: 31423253
J Cell Biochem. 2008 Oct 1;105(2):344-52
pubmed: 18655152
Sci Rep. 2019 Feb 28;9(1):3015
pubmed: 30816188
Cancer Sci. 2012 Aug;103(8):1371-7
pubmed: 22494115
Blood. 2011 Mar 31;117(13):3617-28
pubmed: 21289308
Cancer Res. 2007 Apr 1;67(7):3074-84
pubmed: 17409414
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Oncogene. 2006 Jun 15;25(25):3565-75
pubmed: 16462766
Cancer Treat Rev. 2017 Nov;60:77-89
pubmed: 28898679
Ann Oncol. 2015 Jul;26(7):1385-9
pubmed: 25962440
Oncogene. 2014 May 8;33(19):2454-63
pubmed: 23752186
Nat Genet. 2012 Jul 15;44(8):904-9
pubmed: 22797727
Nat Med. 2017 Mar;23(3):301-313
pubmed: 28191887
Nat Rev Cancer. 2006 Sep;6(9):729-34
pubmed: 16915295
Semin Oncol. 2013 Aug;40(4):421-8
pubmed: 23972705
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Nucleic Acids Res. 2018 Sep 6;46(15):7662-7674
pubmed: 29939287
Oncogene. 2016 May 5;35(18):2311-21
pubmed: 26234679
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Leukemia. 2010 Jan;24(1):81-8
pubmed: 19776757
Eur J Cancer. 2016 Dec;69:226-235
pubmed: 27680407
Nature. 1998 Jul 2;394(6688):92-6
pubmed: 9665135
Haematologica. 2019 Oct 24;:
pubmed: 31649131
Nat Genet. 2011 Sep 25;43(11):1082-90
pubmed: 21946350
Blood. 2001 May 1;97(9):2815-22
pubmed: 11313276
Mol Cell Biol. 1988 Jan;8(1):301-8
pubmed: 2827004
Oncogene. 2017 May 11;36(19):2737-2749
pubmed: 27991928
Science. 2009 Mar 27;323(5922):1747-50
pubmed: 19251594
Oncogene. 2017 Mar;36(11):1573-1584
pubmed: 27617580